A Study of BNT329 in People With Solid Tumors

Full Title

First-in-Human, Open-Label, Multi-Site, Phase I/IIa, Dose Escalation Trial with Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants with Advanced Solid Tumors Known to Express CA19-9

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Eileen O’Reilly’s office at 646-888-4182.

Protocol

26-076

Phase

Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory

Investigator

Eileen M. O'Reilly

Co-Investigators

Kenneth H. Yu

Diseases

Colorectal Cancer
Endometrial and other Uterine Cancers › Endometrial Cancer
Gynecologic Cancer › Ovarian Cancer
Upper Gastrointestinal › Esophageal Cancer

Locations

Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau

ClinicalTrials.gov ID

NCT07186842

ClinicalTrials.gov

Visit ClinicalTrials.gov for full clinical trial description